

We claim:

1. A method for the treatment of behavioral and psychological symptoms in a patient with dementia comprising administering an effective dose of masupirdine, or a pharmaceutically acceptable salt thereof, and an
5 acetylcholinesterase inhibitor or NMDA receptor antagonist, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine, and galantamine or a pharmaceutically acceptable salt thereof; or the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the pharmaceutically acceptable salt of
10 masupirdine is dimesylate monohydrate.
3. The method of claim 1, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.
4. The method of claim 1, wherein the NMDA receptor antagonist is memantine hydrochloride.
- 15 5. A method for the treatment of behavioral and psychological symptoms in a patient with dementia comprising administering an effective dose of masupirdine dimesylate monohydrate and donepezil hydrochloride.
6. A method for the treatment of behavioral and psychological symptoms in a patient with dementia comprising administering an effective dose of
20 masupirdine dimesylate monohydrate and memantine hydrochloride.
7. The method of any one of claims 1 to 6, wherein the behavioral and psychological symptoms in patient with dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability,
25 depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.

8. The method of any one of claims 1 to 7, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, and frontotemporal dementia.
- 5 9. The method of claim 1, wherein the dementia is Alzheimer's disease dementia, and the behavioral and psychological symptoms in patient with Alzheimer's disease dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep
10 and night-time behavior change, and appetite and eating change.
- 10 10. The method of claim 1, wherein the dementia is Parkinson's disease dementia, and the behavioral and psychological symptoms in patient with Parkinson's disease dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety,
15 elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.
11. The method of claim 1, wherein the treatment comprises administering to the patient 25 mg to 125 mg of masupirdine or a pharmaceutically acceptable salt thereof, per day.
- 20 12. The method of claim 1, wherein the treatment comprises administering to the patient 25 mg to 75 mg of masupirdine or a pharmaceutically acceptable salt thereof, per day.
13. The method of claim 1, wherein the treatment comprises administering to the patient 75 mg to 125 mg of masupirdine or a pharmaceutically acceptable salt
25 thereof, per day.
14. The method of claim 1, wherein the treatment comprises administering to the patient 50 mg or 100 mg of masupirdine or a pharmaceutically acceptable salt thereof, per day.

15. The method of claim 1, wherein the treatment comprises administering to the patient 5 mg to 25 mg of donepezil or a pharmaceutically acceptable salt thereof, per day.
- 5 16. The method of claim 1 wherein the treatment comprises administering to the patient 5 mg to 30 mg of memantine or a pharmaceutically acceptable salt thereof, per day.
- 10 17. A pharmaceutical composition, comprising an effective amount of masupirdine or a pharmaceutically acceptable salt thereof, and an acetylcholinesterase inhibitor or NMDA receptor antagonist as claimed in claim 1 for the treatment of behavioral and psychological symptoms in a patient with dementia.
- 15 18. The pharmaceutical composition of claim 17, wherein the behavioral and psychological symptoms in patient with dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.
- 20 19. The pharmaceutical composition of claim 17, wherein the dementia is selected from Alzheimer's disease dementia, dementia associated with schizophrenia, Parkinson's disease dementia, Lewy body dementia, vascular dementia, and frontotemporal dementia.
- 25 20. The pharmaceutical composition of claim 17, wherein the dementia is Alzheimer's disease dementia, and the behavioral and psychological symptoms in patient with Alzheimer's disease dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.

21. The pharmaceutical composition of claim 17, wherein the dementia is Parkinson's disease dementia, and the behavioral and psychological symptoms in patient with Parkinson's disease dementia are selected from agitation/aggression, delusions and/or hallucinations, aberrant motor behavior, aberrant vocalizations, anxiety, elation/euphoria, irritability, depression/dysphoria, apathy, disinhibition, sleep and night-time behavior change, and appetite and eating change.
22. The pharmaceutical composition of claim 17 is administered to the patient by oral, nasal, local, or parenteral routes.
23. The pharmaceutical composition of claim 17 is administered to the patient one to three times per day, one to three times per week, or one to three times per month.